Abingworth’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-1,314,127
| Closed | -$72.3M | – | 21 |
|
|
2022
Q2 | $72.3M | Buy |
1,314,127
+115
| +0% | +$6.03K | 23.14% | 2 |
|
|
2022
Q1 | $42.1M | Buy |
1,314,012
+437,356
| +50% | +$12.5M | 11.95% | 4 |
|
|
2021
Q4 | $19.1M | Hold |
876,656
| – | – | 4.62% | 7 |
|
|
2021
Q3 | $19M | Buy |
876,656
+5,531
| +0.6% | +$111K | 4.32% | 6 |
|
|
2021
Q2 | $16.8M | Hold |
871,125
| – | – | 5.2% | 7 |
|
|
2021
Q1 | $14.7M | Hold |
871,125
| – | – | 5.08% | 9 |
|
|
2020
Q4 | $13.9M | Sell |
871,125
-5,416
| -0.6% | -$75.2K | 4.76% | 7 |
|
|
2020
Q3 | $9.21M | Hold |
876,541
| – | – | 1.97% | 9 |
|
|
2020
Q2 | $10.5M | Hold |
876,541
| – | – | 2.95% | 7 |
|
|
2020
Q1 | $8.59M | Buy |
876,541
+871,124
| +16,081% | +$11.4M | 5.7% | 6 |
|
|
2019
Q4 | $74K | Hold |
5,417
| – | – | 0.04% | 15 |
|
|
2019
Q3 | $83K | Hold |
5,417
| – | – | 0.05% | 13 |
|
|
2019
Q2 | $121K | Sell |
5,417
-28,709
| -84% | -$1.39M | 0.05% | 13 |
|
|
2019
Q1 | $2.31M | Sell |
34,126
-1,985
| -5% | -$127K | 2.06% | 8 |
|
|
2018
Q4 | $1.89M | Hold |
36,111
| – | – | 1.72% | 10 |
|
|
2018
Q3 | $2.46M | Hold |
36,111
| – | – | 1.46% | 13 |
|
|
2018
Q2 | $4.28M | Hold |
36,111
| – | – | 2.44% | 7 |
|
|
2018
Q1 | $2.98M | Buy |
+36,111
| New | +$4.09M | 1.85% | 10 |
|
Other funds holding SRRA
Abingworth's SRRA Position: Q3 2022 in Review
Abingworth sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 1,314,127 shares — an estimated $72.3M sold.
Abingworth first reported a position in SRRA in Q1 2018 and held it in 18 quarters. The position peaked at $72.3M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Abingworth reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Abingworth sold 1,314,127 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $72.3M.
- Abingworth first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 18 quarters.
- Abingworth's Sierra Oncology, Inc. Common Stock position peaked at $72.3M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Abingworth's 13F filing for Q3 2022, filed 10 Nov 2022.